» Articles » PMID: 17079298

The Switch from Latent to Productive Infection in Epstein-barr Virus-infected B Cells is Associated with Sensitization to NK Cell Killing

Overview
Journal J Virol
Date 2006 Nov 3
PMID 17079298
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Following activation of Epstein-Barr virus (EBV)-infected B cells from latent to productive (lytic) infection, there is a concomitant reduction in the level of cell surface major histocompatibility complex (MHC) class I molecules and an impaired antigen-presenting function that may facilitate evasion from EBV-specific CD8+ cytotoxic T cells. In some other herpesviruses studied, most notably human cytomegalovirus (HCMV), evasion of virus-specific CD8+ effector responses via downregulation of surface MHC class I molecules is supplemented with specific mechanisms for evading NK cells. We now report that EBV differs from HCMV in this respect. While latently infected EBV-positive B cells were resistant to lysis by two NK lines and by primary polyclonal NK cells from peripheral blood, these effectors efficiently killed cells activated into the lytic cycle. Susceptibility to NK lysis coincided not only with downregulation of HLA-A, -B, and -C molecules that bind to the KIR family of inhibitory receptors on NK cells but also with downregulation of HLA-E molecules binding the CD94/NKG2A inhibitory receptors. Conversely, ULBP-1 and CD112, ligands for the NK cell-activating receptors NKG2D and DNAM-1, respectively, were elevated. Susceptibility of the virus-producing target cells to NK cell lysis was partially reversed by blocking ULBP-1 or CD112 with specific antibodies. These results highlight a fundamental difference between EBV and HCMV with regards to evasion of innate immunity.

Citing Articles

Entry into the lytic cycle exposes EBV-infected cells to NK cell killing via upregulation of the MICB ligand for NKG2D and activation of the CD56 and NKG2AKIRCD56 subsets.

Desimio M, Covino D, Cancrini C, Doria M Front Immunol. 2024; 15:1467304.

PMID: 39676862 PMC: 11638013. DOI: 10.3389/fimmu.2024.1467304.


Genetics of Primary Hemophagocytic Lymphohistiocytosis.

Karageorgos S, Platt A, Bassiri H Adv Exp Med Biol. 2024; 1448:75-101.

PMID: 39117809 DOI: 10.1007/978-3-031-59815-9_7.


CD56 NK cell expansion correlated with EBV reactivation control post allogeneic hematopoietic stem cell transplantation.

Juan X, Fan Z, Cao X, Ding Y, Liu H, Shang Q Ann Hematol. 2024; 103(9):3723-3735.

PMID: 38862793 DOI: 10.1007/s00277-024-05827-4.


Modulation of Epstein-Barr-Virus (EBV)-Associated Cancers by Co-Infections.

Munz C Cancers (Basel). 2023; 15(24).

PMID: 38136285 PMC: 10741436. DOI: 10.3390/cancers15245739.


Evaluation of host cellular responses to Epstein-Barr virus (EBV) in adult lung transplant patients with EBV-associated diseases.

Zaffiri L, Messinger J, Bush E, Staats J, Patel P, Palmer S J Med Virol. 2023; 95(4):e28724.

PMID: 37185866 PMC: 10481801. DOI: 10.1002/jmv.28724.


References
1.
Cerwenka A, Lanier L . Natural killer cells, viruses and cancer. Nat Rev Immunol. 2002; 1(1):41-9. DOI: 10.1038/35095564. View

2.
Qu L, Rowe D . Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol. 1992; 66(6):3715-24. PMC: 241156. DOI: 10.1128/JVI.66.6.3715-3724.1992. View

3.
Wang E, McSharry B, Retiere C, Tomasec P, Williams S, Borysiewicz L . UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc Natl Acad Sci U S A. 2002; 99(11):7570-5. PMC: 124287. DOI: 10.1073/pnas.112680099. View

4.
Shilling H, Young N, Guethlein L, Cheng N, Gardiner C, Tyan D . Genetic control of human NK cell repertoire. J Immunol. 2002; 169(1):239-47. DOI: 10.4049/jimmunol.169.1.239. View

5.
Keating S, Prince S, Jones M, Rowe M . The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol. 2002; 76(16):8179-88. PMC: 155144. DOI: 10.1128/jvi.76.16.8179-8188.2002. View